Literature DB >> 10826520

A RET double mutation in the germline of a kindred with FMTC.

D K Bartsch1, C Hasse, C Schug, P Barth, M Rothmund, W Höppner.   

Abstract

Activating germline mutations of the RET proto-oncogene are found in more than 90% of families with multiple endocrine neoplasia type 2a (MEN 2a) and familial medullary thyroid carcinoma (FMTC). The majority of patients with these hereditary tumors carry germline mutations that result in the substitution of one of five cysteine residues in exon 10 and 11. Different mutations in exons 13, 14 and 15 affecting non-cysteine residues have also been described but are considered to be rare. We now for the first time report a double mutation of the RET proto-oncogene occurring in the germline of a kindred with FMTC. Both mutations occur within the tyrosine kinase domain in exon 14 and lead to the substitution of valine 804 by methionine and arginine 844 by leucine. Since the double mutated allele cosegregated with the disease and was not identified in 200 unrelated normal probands, we conclude that they represent mutations that predispose the individual to the development of FMTC with a mild phenotype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10826520     DOI: 10.1055/s-2000-5806

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  13 in total

Review 1.  Management of hereditary medullary thyroid carcinoma.

Authors:  Theodora Pappa; Maria Alevizaki
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

2.  Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases.

Authors:  Syed A Ahmed; Karen Snow-Bailey; W Edward Highsmith; Weimin Sun; Raymond G Fenwick; Rong Mao
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

Review 3.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 4.  Multiple endocrine neoplasia type 2.

Authors:  Mariola Peczkowska; Andrzej Januszewicz
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 5.  Molecular pathogenesis of MEN2-associated tumors.

Authors:  Christian A Koch
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 6.  Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease.

Authors:  Michael Brauckhoff; Oliver Gimm; Carl-Ludwig Weiss; Jörg Ukkat; Carsten Sekulla; Katrin Brauckhoff; Phuong Nguyen Thanh; Henning Dralle
Journal:  World J Surg       Date:  2004-11-04       Impact factor: 3.352

Review 7.  [Hereditary thyroid cancer].

Authors:  H Dralle; A Machens; K Lorenz
Journal:  Chirurg       Date:  2008-11       Impact factor: 0.955

Review 8.  Long-term follow up of a "sporadic" unilateral pheochromocytoma revealing multiple endocrine neoplasia MEN2A-2 in an elderly woman.

Authors:  Andreas Weinhäusel; Annemarie Behmel; Bruce A J Ponder; Oskar A Haas; Bruno Niederle; Alois Gessl; Heinrich Vierhapper; Roswitha Pfragner
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

9.  Tandem Germline RET Mutations in a Family Pathogenetic for Multiple Endocrine Neoplasia 2B, Confirmed by a Natural Experiment.

Authors:  Minoru Kihara; Akira Miyauchi; Hiroshi Yoshida; Osamu Yamada; Hiroo Masuoka; Tomonori Yabuta; Takuya Higashiyama; Mitsuhiro Fukushima; Yasuhiro Ito; Kaoru Kobayashi; Akihiro Miya
Journal:  Eur Thyroid J       Date:  2014-12-03

Review 10.  Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene.

Authors:  Andrea Frilling; Frank Weber; Carsten Tecklenborg; Christoph Erich Broelsch
Journal:  Langenbecks Arch Surg       Date:  2003-03-25       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.